Draft Guidance on the inclusion of pregnant women in clinical trials
The US Food and Drug Administration (FDA) has issued draft guidance for industry “Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials” about how and when to include pregnant women in clinical trials for drugs and therapeutic biological products on March 27, 2018. The draft is open for comments and suggestions.
To continue reading this article
Continue reading your article with a Emedinexus account..